Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1622 1634 1674 1675
This examiner grants 0% of resolved cases
Madeline Mcguire Dekarske is an examiner in Art Unit 1622 of Tech Center 1600. She has 2 resolved cases, resulting in an allowance rate of 0.0 percent. This rate provides a baseline for applicants to evaluate the probability of a grant when their case is assigned to her. The 2 resolved cases represent the volume of historical data available for this examiner in Tech Center 1600.
The median time to allowance for applications in her portfolio is 1099 days. Practitioners should also note the interview lift of 0.0 percent. This figure shows that applications involving an interview have not demonstrated a change in the likelihood of allowance compared to those that do not. Within the 1099-day median pendency, practitioners can monitor how the allowance rate develops as more cases reach a final disposition in Art Unit 1622.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18540310 | EGFR INHIBITOR AND PERK ACTIVATOR IN COMBINATION THERAPY AND THEIR USE FOR TREATING CANCER | Non-Final OA | Genentech, Inc. |
| 18684280 | PYRAZINE COMPOUNDS FOR THE CONTROL OF INVERTEBRATE PESTS | Non-Final OA | BASF SE |
| 18290478 | NEW SUBSTITUTED QUINOLINES AS FUNGICIDES | Non-Final OA | BASF SE |
| 18703105 | COMPOSITION | Non-Final OA | SOCIETE DES PRODUITS NESTLE S.A. |
| 18412362 | METHODS AND COMPOSITIONS FOR TREATMENT OF HEART FAILURE WITH PRESERVED EJECTION FRACTION | Non-Final OA | Northwestern University |
| 18578195 | PIPERIDINE DERIVATIVE, AND PHARMACEUTIAL COMPOSITION THEREOF, PREPARATION METHOD THEREFOR, AND USE THEREOF | Non-Final OA | TSINGHUA UNIVERSITY |
| 18550500 | ANTIVIRAL PRODRUGS OF ETV AND FORMULATIONS THEREOF | Final Rejection | THE SCRIPPS RESEARCH INSTITUTE |
| 18692064 | COMPOSITION FOR TREATING, PREVENTING, OR AMELIORATING MELANOMA AND METHOD THEREOF | Non-Final OA | Thomas Jefferson University |
| 18550474 | IMIDAZOPYRIDINYL INHIBITORS OF PLASMA KALLIKREIN | Final Rejection | TAKEDA PHARMACEUTICAL COMPANY LIMITED |
| 18560206 | PSILOCYBIN AND PSILOCIN CONJUGATES FOR TREATMENT OF MENTAL ILLNESSES | Non-Final OA | LONDON PHARMACEUTICALS AND RESEARCH CORPORATION |
| 18546300 | COMBINATION OF A SERCA2 INHIBITOR AND A STING ACTIVATOR FOR USE IN TREATING AND/OR PREVENTING CANCER | Non-Final OA | Université de Montpellier |
| 18329539 | COMPOSITION AND METHODS OF TREATMENT USING SYNERGISTICALLY - ENHANCED SUPPLEMENTATION | Non-Final OA | Xygenyx Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy